KEYTRUDA® (pembrolizumab) KEYNOTE-775 clinical data presentation
Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]
PDF, 2.79 MB
The KEYNOTE-775 study explores KEYTRUDA in combination with lenvatinib, in patients with with confirmed advanced, recurrent, or metastatic endometrial cancer of any histologic subtype, except carcinosarcoma and sarcoma, who had been previously treated with at least one prior platinum-based chemotherapy regimen in any setting.
More information about KEYTRUDA® (pembrolizumab) in endometrial cancer
Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland)
By clicking the links above you will leave the MSD Connect website and be taken to the emc PI portal website